Skip to main content
Clinical Trials/NCT05635396
NCT05635396
Not Yet Recruiting
N/A

A Prospective, Multicenter, Exploratory Study for Epileptic Seizures Detection Through Multimodal Analysis of Cardiorespiratory and Actimetry Parameters

Reliev Technologies0 sites12 target enrollmentDecember 15, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Epilepsy; Seizure
Sponsor
Reliev Technologies
Enrollment
12
Primary Endpoint
Number of false positive seizures.
Status
Not Yet Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Epilepsy is a disabling neurological disease that affects tens of millions of people worldwide. Despite therapeutic advances, about a third of these patients suffer from treatment-resistant forms of epilepsy and still experience regular seizures.All seizures can last and lead to status epilepticus, which is a major neurological emergency. Epilepsy can also be accompanied with cognitive or psychiatric comorbidities.

Reliable seizures count is an essential indicator for estimating the care quality and for optimizing treatment. Several studies have highlighted the difficulty for patients to keep a reliable seizure diary due for example to memory loss or perception alterations during crisis. Whatever the reasons, it has been observed that at least 50% of seizures are on average missed by patients.

Seizure detection has been widely developed in recent decades and are generally based on physiological signs monitoring associated with biomarkers search and coupled with detection algorithms. Multimodal approaches, i.e. combining several sensors at the same time, are considered the most promising.

Mobile or wearable non invasive devices, allowing an objective seizures documentation in daily life activities, appear to be of major interest for patients and care givers, in detecting and anticipating seizures occurence.

This single-arm exploratory, multicenter study aims at assessing whether the use of such a non-invasive, wearable device can be useful in a real life setting in detecting seizures occurence through multimodal analysis of various parameters (heart rate, respiratory and accelerometry).

Registry
clinicaltrials.gov
Start Date
December 15, 2022
End Date
March 15, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients aged 7 years old or more
  • Patients with drug-resistant focal epilepsy
  • Patients with high frequency seizures according to investigator's judgement
  • Patients that can be followed 4 weeks after inclusion
  • Informed consent form signed.

Exclusion Criteria

  • Generalised tonic-clonic seizures
  • Frequent psychogenic non-epileptic seizures
  • Pregnant or breastfeeding patients
  • Patients displaying sensor contraindications

Outcomes

Primary Outcomes

Number of false positive seizures.

Time Frame: From baseline up to 4 weeks.

The number of false positive seizures will be measured, ie. seizures detected through the sensor but not reported in the seizures diary completed in real time by care giver.

Number of true positive seizures.

Time Frame: From baseline up to 4 weeks.

The number of true positive seizures will be measured, ie. seizures detected through the sensor and reported in a seizures diary completed in real time by care giver.

Number of false negative seizures.

Time Frame: From baseline up to 4 weeks.

The number of false negative seizures will be measured, ie. seizures not detected through the sensor but reported in the seizures diary completed in real time by care giver.

Secondary Outcomes

  • Sensor tolerability from care givers' perspective.(At 4 weeks after baseline.)
  • Respiration rate impact on seizures detection.(From baseline up to 4 weeks.)
  • Changes in Number of true positive, true negative and false negative seizures throughout the study duration.(From baseline up to 4 weeks.)
  • Electrocardiogram signal quality in real life setting.(From baseline up to 4 weeks.)
  • Activity impact on seizures detection.(From baseline up to 4 weeks.)
  • Body orientation impact on seizures detection.(From baseline up to 4 weeks.)
  • Changes in number of true positive, true negative and false negative seizures depending on patients' characteristics.(From baseline up to 4 weeks.)
  • Sensor tolerability from patients' perspective.(At 4 weeks after baseline.)
  • ECG data impact (ECG characteristics) on seizures detection.(From baseline up to 4 weeks.)
  • Heart rate impact on seizures detection.(From baseline up to 4 weeks.)

Similar Trials